GLP-1 Drugs and Muscle Loss: What the Research Shows

The GLP-1 weight loss drugs (semaglutide as Ozempic and Wegovy, tirzepatide as Mounjaro and Zepbound) work. The headline numbers from the registration trials are real. Average users lose 15 percent of their body weight on semaglutide and as much as 22 percent on tirzepatide over a year or so. Those are pharmacological numbers nobody had access to a decade ago.

The quieter half of that picture is body composition. Some of what comes off is fat. Some of it is muscle, bone, organ tissue, and connective tissue. That second bucket (lean mass on a DXA scan) matters for strength, metabolic health, fall risk in older adults, and the rate at which weight regains if therapy stops. The trial substudies have now reported their lean-mass numbers, and the popular conversation has gone from "Ozempic causes muscle wasting" to "actually it preserves muscle" depending on who is talking. The truth sits between those two camps.

This article walks through the five trials and reviews that anchor the modern picture (Wilding 2021 for STEP 1, the STEP 1 body composition substudy, Look 2025 for SURMOUNT-1, the Neeland 2024 review on lean mass with GLP-1s, and the older Cava 2017 protein-during-weight-loss synthesis). We will close with the lifestyle plan the 2024 and 2025 reviews actually recommend.

The Research: What Studies Show

Three trial-level papers and two reviews carry most of the weight here. We will go in order of strength.

STEP 1 (Wilding et al. 2021): The Headline Semaglutide Result

The pivotal trial for semaglutide in obesity was Wilding et al. (2021), published in the New England Journal of Medicine. The team randomized 1,961 adults with obesity (or overweight plus a weight-related condition) to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks. Both arms also got lifestyle counseling at each visit.

The primary outcome was clear. Semaglutide produced a mean weight loss of 14.9 percent versus 2.4 percent for placebo. About 86 percent of the semaglutide group lost at least 5 percent of body weight. The trial established the modern era of pharmacological weight loss and led directly to FDA approval of Wegovy.

What it did not establish was what tissue the weight came from. That question went to a substudy.

STEP 1 Body Composition Substudy (Wilding et al. 2021): The Lean Mass Question

A subset of 140 participants (95 on semaglutide, 45 on placebo) got DXA scans at baseline and at week 68. The results were published as a companion paper in Diabetes, Obesity and Metabolism (Wilding et al. 2021, PMC8089287).

Total fat mass dropped 19.3 percent. Visceral fat dropped 27.4 percent. Lean body mass dropped 9.7 percent. The proportion of total body mass made up of lean tissue actually went up by 3.0 percentage points, which is the metric the manufacturer highlighted. But the absolute lean mass loss was meaningful. About 6.9 kg of the average 15.3 kg lost was lean tissue. That is roughly 45 percent of total weight lost coming from lean mass.

The framing matters. A 45 percent lean-mass fraction is on the high side for rapid weight loss but is not categorically different from what a very low calorie diet without resistance training produces. It is the size of the weight loss multiplied by that ratio, not the ratio itself, that drives the absolute kilograms of muscle lost.

SURMOUNT-1 Body Composition Substudy (Look et al. 2025)

The parallel question for tirzepatide came from Look et al. (2025), published in Diabetes, Obesity and Metabolism. The substudy reported DXA changes from baseline to week 72 in the SURMOUNT-1 cohort, where average total weight loss approached 22 percent on the highest dose.

Total fat mass dropped 33.9 percent. Total lean mass dropped 10.9 percent. The fat-mass to lean-mass ratio improved substantially. Of the total kilograms lost, approximately 75 percent came from fat and 25 percent from lean tissue. That 25 percent lean-mass fraction is roughly in line with what you would see from supervised diet plus exercise in a controlled trial.

The cleaner ratio in SURMOUNT-1 versus STEP 1 is genuinely interesting. Tirzepatide is a dual GIP/GLP-1 agonist, and the GIP component may affect fat versus lean partitioning slightly differently. The honest read is that the two drugs are closer than the marketing makes them sound, and the lean-mass fraction depends as much on lifestyle context (protein, activity) as on the molecule. A 2026 real-world digital phenotyping preprint actually flipped the picture in routine care, suggesting tirzepatide users in non-trial settings lose slightly more lean mass than semaglutide users, possibly because they lose more total weight.

Neeland et al. 2024: The Review That Sets Expectations

The cleanest synthesis of the lean-mass question is Neeland, Linge, and Birkenfeld (2024) in Diabetes, Obesity and Metabolism. The authors reviewed the available GLP-1 trials with body composition data and concluded that the lean-mass loss seen in GLP-1 therapy is in the expected range for the magnitude of weight loss observed. Across studies, roughly 20 to 40 percent of total weight lost came from lean tissue, depending on the population, baseline body composition, and lifestyle conditions.

The same review emphasizes the lifestyle lever. It recommends resistance training at least twice per week and protein intakes in the 1.2 to 1.6 g per kg per day range for anyone on GLP-1 therapy, especially older adults and anyone at risk of sarcopenia. The review is the basis for the current clinical practice guidance most endocrinology departments now give patients starting GLP-1 therapy.

Cava et al. 2017: The Protein-During-Weight-Loss Reference

The protein guidance is not new. Cava, Yeat, and Mittendorfer (2017) in Advances in Nutrition reviewed the muscle-preservation-during-weight-loss literature long before GLP-1s were on the public radar. Their conclusion held up. A hypocaloric diet with adequate protein (above the RDA, typically 1.2 to 1.6 g per kg per day) combined with resistance training preserves muscle mass and strength better than diet alone. Bone density and physical function track the same direction.

That paper, plus Sardeli et al. (2018) in Nutrients, are the reference points the 2024 Neeland review cites when it makes the resistance-training-plus-protein recommendation. Nothing about the GLP-1 era invalidated the older literature. It just made the recommendation more urgent because the weight loss is faster and larger.

Why GLP-1 Weight Loss Pulls Muscle Along With Fat

This is where the popular discussion goes sideways. The drugs themselves do not directly catabolize muscle. They suppress appetite and slow gastric emptying. That produces a sustained caloric deficit, often 500 to 1,000 calories per day. The body responds to that deficit the way it always has. Fat tissue gets oxidized for fuel. So does some lean tissue. The ratio depends on three things, in order of importance.

First, protein intake. The body needs amino acids to maintain skeletal muscle. If dietary protein falls below the maintenance threshold (around 0.8 g per kg per day for sedentary adults, higher during weight loss), the body cannibalizes muscle to supply those amino acids. GLP-1 users frequently eat less than usual across the board, and protein gets shortchanged because high-protein foods tend to be filling and the appetite is already gone.

Second, mechanical loading. Muscle responds to use. If a muscle is not stimulated by resistance work, the body has no signal to maintain it during a deficit. This is why even modest resistance training preserves lean mass during weight loss. The signal does not need to be intense. It needs to be present.

Third, rate of weight loss. The faster the loss, the more lean tissue gets dragged along for the ride. GLP-1 users routinely lose weight faster than what behavioral interventions alone produce, which pushes the lean-mass fraction up. That is unavoidable without slowing the dose or pausing the medication, neither of which most users want to do.

The mechanism is the same as detraining. Muscle held in a low-stimulus, low-fuel environment shrinks. Adding resistance work and adequate protein flips both signals. It is a deeply unsurprising story when you strip away the brand-name framing.

For the broader context on how exercise interacts with GLP-1 therapy, our blog on Ozempic and exercise covers the practical side of training while on the medication. The piece on resistance training and mortality covers why preserving lean mass matters far beyond weight loss.

How to Preserve Muscle While on a GLP-1

The 2024 and 2025 reviews converge on a simple three-part plan. None of it requires a gym, expensive equipment, or a personal trainer.

Resistance training two or three times a week. Hit the major muscle groups (legs, hips, chest, back, shoulders, arms, core) with two or three working sets per exercise. Use bodyweight progressions, resistance bands, or dumbbells. The dose that preserves muscle is much lower than the dose that builds new muscle. Around 10 hard sets per major muscle group per week is enough during a deficit, which is comfortably in reach for a 25-minute home session three times a week. For the schedule logic behind that number, see our piece on training frequency for muscle growth.

Protein at 1.2 to 1.6 g per kg per day. For someone weighing 80 kg (176 lb), that is 96 to 128 grams of protein per day. Anchor every meal around a protein source. Eggs, Greek yogurt, cottage cheese, chicken, fish, tofu, tempeh, lentils, and protein powder are the workhorses. If appetite is the bottleneck (and on a GLP-1 it usually is), prioritize protein-dense foods over volume foods. A scoop of protein powder in coffee or a Greek yogurt can replace an entire meal's worth of protein with very little stomach load.

Daily walking on top of the resistance work. The 2024 Neeland review and the 2025 ACE practice review both note that overall daily activity matters. Walking does not preserve muscle the way resistance work does, but it preserves cardiovascular fitness and supports the energy availability that makes the higher protein intake actually contribute to lean mass. Aim for the equivalent of 7,000 to 10,000 steps a day, less if you are starting from a lower baseline.

If you are over 60 or already at risk for sarcopenia, the same plan applies, just earlier in the dose-escalation phase. The 2024 review specifically recommends starting resistance training the same week you start the GLP-1, not waiting until weight loss plateaus. The lean tissue that comes off in the first three months is the hardest to recover later.

Common Misconceptions

Misconception 1: "GLP-1 drugs uniquely destroy muscle."

They do not. The body composition substudies put the lean-mass fraction at roughly 25 to 45 percent of total weight lost, depending on the drug and the population. That range is well within what unsupervised diet-only weight loss produces. What is unique is the magnitude. Losing 15 percent of body weight in a year produces more absolute kilograms of lean tissue loss than losing 5 percent, even at the same fractional ratio. The drug is not the villain. The deficit is, and the lifestyle around the deficit is what determines the outcome.

Misconception 2: "If lean mass percentage goes up, muscle is being preserved."

Sponsors often report the proportion of body mass that is lean tissue, which improves on GLP-1s because fat mass falls faster than lean mass. That metric is genuinely good news in one sense (the user is leaner overall) but it is not the same as preserving muscle. Absolute lean mass still went down in both STEP 1 and SURMOUNT-1. A user can have a better body-composition ratio and less skeletal muscle at the same time. The clinically relevant question is whether absolute lean mass and function are preserved, and the substudies say partly, not fully.

Misconception 3: "I need a gym to preserve muscle on a GLP-1."

You do not. The Sardeli 2018 meta-analysis pooled trials that used machines and free weights, but the muscle-preserving mechanism (mechanical loading at a meaningful dose, two or three times a week) is reproducible with bodyweight squats, push-up progressions, single-leg work, resistance band rows, and dumbbell variations. The barrier to muscle preservation on a GLP-1 is consistency and protein, not equipment access. A 25-minute home session three times a week is enough to flip the body's signal from "shed this tissue" to "maintain this tissue".

What the Research Suggests Going Forward

Pull back the camera and the GLP-1 lean-mass picture is mostly settled at the trial level. The drugs work for weight loss. They also pull lean tissue along at roughly the proportion you would expect for the magnitude of loss. The 2024 Neeland review and the 2025 ACE practice review both conclude that the lifestyle prescription (resistance training plus protein) is well-established and should be paired with every GLP-1 prescription, not held in reserve for users who plateau or regain.

Three caveats stay in play. First, the substudies are short. STEP 1 and SURMOUNT-1 ran 68 to 72 weeks. Long-term users on these drugs for five or ten years are an open question. Whether the early lean-mass loss is recovered, stable, or worsens slowly over years has not been characterized at the trial level. Second, the participant pool skews younger and lower-risk than the real-world GLP-1 user base. Adults over 65, frail adults, and adults with sarcopenia at baseline are underrepresented. The 2024 review flags that group as the one most in need of structured exercise support. Third, the absolute magnitude of lean mass loss in trials masks substantial individual variation. Some users lose much less than the trial average. Others lose substantially more. The honest takeaway is that average outcomes are okay, individual outcomes can be much worse, and the lifestyle factors that close that variance are well-known and accessible.

The practical advice is genuinely simple. Pair the medication with resistance training two or three times a week, protein at 1.2 to 1.6 g per kg per day, and daily walking. Track grip strength, walking speed, or your ability to stand up from a chair without using your hands. If those numbers hold over the months of weight loss, the muscle that came off was metabolically acceptable. If they decline, the dose of training and protein has to go up.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine 384.11 (2021): 989-1002. PMID: 33567185
2. Wilding JPH, Batterham RL, Davies M, et al. "Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study." Diabetes, Obesity and Metabolism (2021). PMC8089287
3. Look M, Dunn JP, Kushner RF, et al. "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight." Diabetes, Obesity and Metabolism 27.5 (2025): 2720-2729. DOI: 10.1111/dom.16275
4. Neeland IJ, Linge J, Birkenfeld AL. "Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies." Diabetes, Obesity and Metabolism 26.Suppl 4 (2024): 16-27. DOI: 10.1111/dom.15728
5. Cava E, Yeat NC, Mittendorfer B. "Preserving Healthy Muscle during Weight Loss." Advances in Nutrition 8.3 (2017): 511-519. PMC5421125
6. Sardeli AV, Komatsu TR, Mori MA, Gáspari AF, Chacon-Mikahil MPT. "Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis." Nutrients 10.4 (2018): 423. PMID: 29596307